Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE−/− mice
Xuedong Bai, Wenjie Fei, Jingzhou Fang, Chaomin Kong, Yaqi Xiang, Yuele Tian, Limin Wei · 2026
Read Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE−/− mice by Xuedong Bai, Wenjie Fei, Jingzhou Fang, Chaomin Kong, Yaqi Xiang, Yuele Tian, Limin Wei (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0359161.txt.
Description
Xuedong Bai and six colleagues test a liver targeted drug against artery disease in mice, in PLOS ONE in 2026. Atherosclerosis grows from a mix of blood fats and vessel wall inflammation, and few drugs press both levers at once. Resmetirom switches on a thyroid hormone receptor mainly in the liver and is known for improving fat metabolism. Whether it also calms inflamed vessels was the open question.
Mice bred to develop the disease ate a high fat diet, then received the drug at two doses or a dummy treatment for eight weeks. Treated mice carried less plaque in the aorta, showed healthier blood fat patterns, and had quieter activity in a key inflammation switch inside vessel tissue, with stronger effects at the higher dose. The results support wider testing of the drug's vessel benefits beyond the liver.
Catalog record
| CREATOR | Xuedong Bai, Wenjie Fei, Jingzhou Fang, Chaomin Kong, Yaqi Xiang, Yuele Tian, Limin Wei |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23349 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |